Blog
RSS FeedPosted by Michael Wonder on 15 Mar 2017
Sanofi displeased with NICE decision on rare disease drug
14 March 2017 - French drug major Sanofi and its specialty care global business unit, Sanofi Genzyme, say they are ...
Posted by Michael Wonder on 14 Mar 2017
NICE publishes Appraisal Consultation Document for nivolumab (Opdivo)
14 March 2017 - The Department of Health has asked the NICE to produce guidance on the use of nivolumab in ...
Posted by Michael Wonder on 06 Mar 2017
NICE publishes draft guidance on the use of etelcalcetide for secondary hyperparathyroidism
3 March 2017 - The Department of Health has asked the NICE to produce guidance on the use of etelcalcetide hydrochloride ...
Posted by Michael Wonder on 02 Mar 2017
NICE expands positive recommendation for Erbitux as first-line treatment for RAS wild type mCRC
2 March 2017 - NICE’s recommendation is a significant step forward in Merck’s aspiration to ensure cancer patients have optimal ...
Posted by Michael Wonder on 02 Mar 2017
NICE recommends Ocaliva (obeticholic acid) for the treatment of patients with primary biliary cholangitis in England, Wales and Northern Ireland
2 March 2017 - Rapid NICE approval only two months after marketing authorisation in the EU; one of the fastest ...
Posted by Michael Wonder on 28 Feb 2017
NICE publishes draft guidance on Keytruda
28 February 2017 - The Department of Health has asked NICE to produce guidance on using pembrolizumab in the NHS in ...
Posted by Michael Wonder on 21 Feb 2017
NICE publishes draft guidance for eluxadoline
21 February 2017 - The Department of Health has asked NICE to produce guidance on using eluxadoline in the NHS in ...
Posted by Michael Wonder on 15 Feb 2017
NICE rejects Alexion’s rare disease therapy Kanuma
15 February 2017 - NICE has published a final evaluation determination rejecting the use of Alexion's Kanuma to treat infants, ...
Posted by Michael Wonder on 15 Feb 2017
NICE publishes draft guidance for Venclyxto
15 February 2017 - The Department of Health has asked NICE to produce guidance on using venetoclax in the NHS in ...
Posted by Michael Wonder on 13 Feb 2017
NICE approves Incyte’s leukaemia drug for routine NHS use
13 February 2017 - NICE published draft guidance recommending ponatinib (Iclusig) for routine use on the NHS, to treat some ...
Posted by Michael Wonder on 07 Feb 2017
Alexion 'extremely disappointed' with NICE ruling on costly Strensiq
7 February 2017 - Once again, the U.K.’s drug cost watchdogs are catching flak from the industry after issuing a ...
Posted by Michael Wonder on 04 Feb 2017
Most important breast cancer drug in two decades will not get NHS funding
3 February 2017 - A new drug described as one of the "most important" advances in treating breast cancer ...
Posted by Michael Wonder on 03 Feb 2017
Breast cancer drug costs too high in relation to benefits for routine NHS funding
3 February 2017 - NICE does not recommend breast cancer drug palbociclib (Ibrance, Pfizer) because its cost is too high in ...
Posted by Michael Wonder on 26 Jan 2017
Final yes from NICE for Gilead’s Epclusa
26 January 2017 - NICE has now published final guidance endorsing Epclusa as an option for the treatment of adults ...
Posted by Michael Wonder on 25 Jan 2017
NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation
25 January 2017 - NICE published guidance that recommended ibrutinib for chronic lymphocytic leukaemia in adults who have had at ...